Pharma news

Reset all filters
Geography
Company
Refine search
Illumina prevails against BGI at English High Court
Pharma
Illumina has secured a victory in its patent dispute with Chinese genome sequencing company BGI at the English High Court, which ruled that four of its patents had been infringed.   21 January 2021
USITC to probe alleged engineered-rice theft by Chinese company
Americas
The US International Trade Commission is to investigate allegations that a Chinese company infringed patents held by Ventria Bioscience by importing genetically-engineered rice seeds for medical purposes.   19 January 2021
Pfizer sues India generic drugmaker over cancer drug
Pharma
Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.   14 January 2021
Americas
Pharmaceutical company MSD has urged a federal court to rule that its new vaccine doesn’t infringe three patents owned by Pfizer’s subsidiary, Wyeth, because they are invalid.   14 January 2021
Pharma
Sanofi will buy British immunotherapy firm Kymab for up to $1.45 billion, as it seeks to expand in the rapidly growing immunotherapy field.   12 January 2021
Americas
Roche has asked the US Supreme Court to declare that methods of separating DNA are not patent-eligible.   8 January 2021
Americas
Generic drug makers are trying to persuade the US Supreme Court to retain an administrative process for challenging patents, in the latest bid to discredit the controversial decision handed down in Arthrex v Smith & Nephew.   7 January 2021
Americas
Chemical manufacturers have a renewed opportunity to protect the confidentiality of the chemicals they make or import, according to an announcement by the US Environmental Protection Agency.   7 January 2021
Pharma
A licensing pathway that will reduce the time it takes for novel medicines to enter the marketplace has been launched by the UK Medicines and Healthcare products Regulatory Agency.   7 January 2021
Americas
Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31.   5 January 2021